BB Biotech AG

The share price of BB Biotech increased by 3.1% in CHF in January, while the company’s net asset value (NAV) rose by 3.4% in USD. The Nasdaq Biotechnology Index (NBI) closed 2.5% higher in USD.

The year began with the J.P. Morgan Healthcare Conference, which set a constructive tone for the biotechnology sector. Management teams broadly highlighted stable operating trends and increasing confidence in pipeline progress and commercial execution. Investor attention focused on companies combining late-stage assets, clear regulatory pathways and established or emerging revenue bases. Strategic buyers reiterated the importance of external innovation for R&D productivity, while capital markets continued to reopen in a measured, data-driven manner. This was reflected in improved funding activity in January, driven primarily by follow-on financings and resilient private and venture capital markets, while IPO activity remained selective and cell and gene therapy financing started the year at a slower pace.

Macroeconomic developments gained relevance as the month progressed. The US dollar weakened at times, contributing to cross-asset volatility, while higher policy uncertainty kept markets sensitive to headline risk. Debate around the future leadership and perceived independence of the Federal Reserve added to this uncertainty, reinforcing cautious market positioning. Expectations for monetary easing evolved more gradually than previously anticipated, with discount-rate pressure easing only incrementally. Ongoing geopolitical and trade-related developments added to short-term market fluctuations.

Within biotechnology, volatility remained elevated but was increasingly driven by company-specific events. Clinical data releases, regulatory decisions, financing activity and earnings updates led to pronounced performance dispersion across the sector. Positive execution and high-quality data continued to be rewarded, while disappointments were met with swift repricing, occasionally amplified by broader market moves.

Overall, January reinforced a renewed focus on fundamentals and selective risk taking. For biotechnology, the environment continues to favour active management, with emphasis on data quality, clear catalyst visibility, credible commercial execution and disciplined capital allocation. While improved follow-on and private financing activity supports sector liquidity, ongoing macro and policy uncertainty underscores the importance of balance-sheet strength and risk management, particularly for earlier-stage companies.

Selected highlights in January from BB Biotech’s portfolio companies:

Revolution Medicines (+22%, in USD) rose sharply in January, driven primarily by renewed market speculation around potential strategic interest. The share price reaction followed increased takeover rumours, reflecting the company’s growing strategic relevance within the oncology landscape, particularly in the context of sustained M&A appetite for differentiated RAS-targeted platforms.
Beyond speculation, investor discussions highlighted the underlying fundamentals supporting this interest. Revolution Medicines continues to make steady clinical progress across its pipeline, with a focus on KRAS-driven solid tumours and opportunities to expand into combination regimens and earlier treatment lines. Management reiterated confidence in execution and its long- term development plans at recent investor meetings.

Immunocore Holdings (-6%, in USD) declined in January. The share price movement was not driven by negative clinical data, but by a more cautious reassessment of execution and longer-term pipeline visibility.
Investor sentiment was also influenced by the announced departure of the Head of Research, which introduced short-term uncertainty around research leadership and pipeline continuity. Management communicated that the transition is orderly and does not alter the company’s strategic priorities or ongoing development programs. Market attention remained focused on the commercial trajectory of KIMMTRAK and on progress across the broader TCR platform.